Amantadine is sometimes used to treat fatigue in multiple sclerosis.
Objectives:
To report a patient with secondary progressive multiple sclerosis (SPMS) who developed late-onset side effects of amantadine which were initially felt to represent a progression of her SPMS.
Methods:
A single retrospective case report.
Results:
Symptoms of cognitive deterioration, ataxia and hallucinations resolved completely on cessation of the amantadine she had been prescribed several years beforehand.
Conclusion:
Clinicians involved in the management of the symptoms of SPMS should be aware of the potential for cumulative side effects of drugs used to treat symptoms and consider their potential role in precipitating neurological deterioration.
MindenSLFrankelDHaddenL, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: Methods and sample characteristics. Mult Scler2006; 12(1): 24–38.
2.
YangT-TWangLDengX-Y, et al. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci2017; 380: 256–261.
3.
NICE Guideline Development Group. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care, 2014, http://www.ncbi.nlm.nih.gov/pubmed/25340249 (accessed 13 September 2015).
4.
PucciEBranãsPD’AmicoR, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev2007; 2007: CD002818.
5.
NourbakhshBRevirajanNMorrisB, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: A randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol2021; 20(1): 38–48.
6.
ManjalyZMHarrisonNACritchleyHD, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry2019; 90(6): 642–651.
7.
MillerPSoundyA.The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis. J Neurol Sci2017; 381: 41–54.
8.
BerryASShahVDBakerSL, et al. Aging affects dopaminergic neural mechanisms of cognitive flexibility. J Neurosci2016; 36: 12559–12569.
9.
KöppelCTenczerJ.A revision of the metabolic disposition of amantadine. Biomed Mass Spectrom1985; 12(9): 499–501.
